Sarepta Therapeutics (SRPT) said a third patient has died from acute liver failure after receiving one of its gene therapies, intensifying scrutiny over the safety of its treatments, Bloomberg ...

The VVD and D66 want to expand the Embryo Act to allow parents to test embryos for hereditary diseases. Currently, embryo ...

A 51-year-old man died last month after receiving an experimental treatment from Sarepta, the third death this year tied to ...

At the FDA's request, delandistrogene moxeparvovec (Elevidys), the only approved gene therapy for Duchenne muscular dystrophy ...

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Disabled Oasis fan Mark Chapman has slammed gig organisers after witnessing dozens of fans on the accessible platform at Heaton Park stand and abandon mobility aids when the band began playing. Mark, ...

The company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.

Norwegian documentary, The Remarkable Life of Ibelin, directed by Benjamin Ree, chronicles the life of Mats Steen, who had ...

New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular ...

Sarepta Therapeutics said it will eliminate 36% of its workforce—approximately 500 jobs—in a restructuring that follows the ...